Nanomedicine is a type of cutting-edge technology which refers to the medical application of nanotechnology. Using innovation and precision, we plan to intertwine the effectiveness of nanomedicine with treating tumors effectively. This research concentrates on an poly(ethylene glycol) methyl ether (mPEG) polymer-lipid conjugate that was synthesized in order to create micelles. Polyethylene glycol (PEG) is a polymer that is widely used in drug delivery in order to create more stable nanoparticles. This is an imperative contribution to our research because of the suppression provided by the PEG coatings to the nanoparticles, allowing the nanoparticles to escape immune system detection and therefore prolong blood circulation time. Typically, there are two different types of lipid nanoparticles that have been used in nanomedicine as carriers. Firstly, liposomes which consist of a lipid bilayer enclosing an aqueous core that is on the order of 100s of nanometers. Micelles, on the other hand, are about a tenth the size of a liposome, and are made up of a lipid monolayer, with no aqueous core. They are a type of small nanocarrier that can penetrate deeper into solid tumors than conventional nanoparticles which makes them more favorable in our lab. In order to create these micelles, a highly curved branched PEG-lipid is being synthesized, whereby two mPEG molecules (350 and 2K) are conjugated to a lipid. Because of the high curvature on branched- PEG lipids, the formation of micelles is much easier. We hypothesize that because of this size difference, micelles will be able to penetrate a tumor better and ultimately be more effective as a drug carrier. The synthesis of this molecule is being completed using methods such as extractions, precipitation, mass spectroscopy, and thin layer chromatography. Following completion of this 350-2k asymmetric branched PEG lipid, it will be used to form micelles and will be evaluated for its potential to deliver anticancer drugs